Zacks Research Issues Positive Estimate for TBPH Earnings

Theravance Biopharma, Inc. (NASDAQ:TBPH) – Stock analysts at Zacks Research lifted their Q3 2025 EPS estimates for Theravance Biopharma in a research note issued to investors on Monday, October 21st. Zacks Research analyst R. Department now forecasts that the biopharmaceutical company will earn ($0.03) per share for the quarter, up from their previous forecast of ($0.09). The consensus estimate for Theravance Biopharma’s current full-year earnings is ($1.04) per share. Zacks Research also issued estimates for Theravance Biopharma’s FY2025 earnings at ($0.01) EPS, Q1 2026 earnings at ($0.07) EPS, Q2 2026 earnings at ($0.04) EPS and FY2026 earnings at $0.55 EPS.

Theravance Biopharma (NASDAQ:TBPH) last issued its earnings results on Monday, August 5th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.25). The business had revenue of $14.26 million for the quarter, compared to analyst estimates of $15.81 million. Theravance Biopharma had a negative return on equity of 21.29% and a negative net margin of 73.61%. During the same period last year, the company posted ($0.28) earnings per share.

A number of other equities research analysts have also recently weighed in on the company. TD Cowen cut their price target on Theravance Biopharma from $10.00 to $9.00 and set a “hold” rating on the stock in a report on Tuesday, August 6th. HC Wainwright reiterated a “buy” rating and set a $15.00 price target on shares of Theravance Biopharma in a research report on Monday, September 16th. Leerink Partners lowered Theravance Biopharma from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $15.00 to $10.00 in a report on Tuesday, August 6th. Leerink Partnrs downgraded shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 6th. Finally, StockNews.com cut shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Saturday, August 10th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $13.75.

Theravance Biopharma Price Performance

NASDAQ:TBPH opened at $8.64 on Wednesday. The firm has a market capitalization of $420.19 million, a P/E ratio of -10.05 and a beta of 0.25. The business has a 50 day simple moving average of $8.21 and a 200 day simple moving average of $8.76. Theravance Biopharma has a 12-month low of $7.44 and a 12-month high of $11.71.

Insider Activity at Theravance Biopharma

In other Theravance Biopharma news, major shareholder Eli Samaha purchased 999,800 shares of the company’s stock in a transaction dated Wednesday, August 7th. The shares were bought at an average price of $7.80 per share, for a total transaction of $7,798,440.00. Following the purchase, the insider now directly owns 9,511,150 shares in the company, valued at $74,186,970. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. 6.90% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of TBPH. Kennedy Capital Management LLC boosted its holdings in Theravance Biopharma by 3.7% in the 1st quarter. Kennedy Capital Management LLC now owns 38,202 shares of the biopharmaceutical company’s stock valued at $343,000 after purchasing an additional 1,359 shares during the period. Price T Rowe Associates Inc. MD increased its stake in Theravance Biopharma by 7.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 49,475 shares of the biopharmaceutical company’s stock valued at $444,000 after acquiring an additional 3,532 shares during the period. State Board of Administration of Florida Retirement System increased its stake in Theravance Biopharma by 28.2% during the first quarter. State Board of Administration of Florida Retirement System now owns 22,671 shares of the biopharmaceutical company’s stock valued at $203,000 after acquiring an additional 4,990 shares during the period. American Century Companies Inc. raised its holdings in Theravance Biopharma by 11.7% in the 2nd quarter. American Century Companies Inc. now owns 57,611 shares of the biopharmaceutical company’s stock valued at $489,000 after acquiring an additional 6,026 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Theravance Biopharma by 16.6% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 52,876 shares of the biopharmaceutical company’s stock worth $474,000 after acquiring an additional 7,509 shares during the period. Institutional investors own 99.10% of the company’s stock.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.